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BACKGROUND/PURPOSE: An increase in incidence of Clostridium difficile infection (CDI) among 
Western countries has been noted in recent years. Epidemiological data of CDI are scarce in Taiwan. This 
study is intended to depict the clinical features of CDI at a medical center in Southern Taiwan.
METHODS: From January 1, 2007 to March 31, 2008, hospitalized patients with CDI (defined as the 
presence of gastrointestinal symptoms and fecal C. difficile toxin) were identified. Their medical records 
were reviewed for further evaluation.
RESULTS: A total of 86 cases of CDI were identified in the study period. The incidence was 42.6 cases per 
100,000 patient-days, or 3.4 cases per 1,000 discharges, and was highest in intensive care units (110.6 cases 
per 100,000 patient-days). Variable incidence rates were noted in different wards, and prevalence was 
higher in the infectious ward. Diarrhea, fever, and abdominal distension were common in 82 (95.3%), 47 
(54.7%), and 29 (33.7%) patients, respectively. Metronidazole was the initial therapeutic regimen for 83 
(96.5%) patients. Prolonged diarrhea was noted in 31 (36.4%) patients, especially in those on hemodialysis 
therapy. Recurrence was noted in 7 (8.1%) patients. Fecal carriage of vancomycin-resistant Enterococcus 
colonization was found in three patients after therapy for CDI. All-cause mortality rate of patients with 
CDI at 30 days was 23.3%.
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Introduction
Clostridium difficile is a Gram-positive, anaerobic, spore-
forming bacillus that was first described in 1935 by Hall 
and O’Toole as part of the normal flora of neonates.1 By 
1978, C. difficile was proven to be the etiologic pathogen 
of antibiotic-associated colitis.2 Clinical manifestations 
of C. difficile infections (CDI) range from asymptomatic 
colonization, mild to severe diarrhea, pseudomembranous 
colitis, toxic megacolon, and even death.3 C. difficile has been 
responsible for 10–25% of antibiotic-associated diarrhea 
cases, and 90–100% of those with antibiotic-associated 
pseudomembranous colitis.3,4
Over the last decade, the incidence of CDI has progres-
sively increased in both the United States and the United 
Kingdom.5,6 A hypervirulent strain, North American pulse-
field type 1, or PCR ribotype 027 NAP1/027, has resulted 
in increasing mortality rates.7 Despite the fact that the 
English literature concerning C. difficile infection is volu-
minous, epidemiological data regarding CDI is scarce in 
Taiwan. Therefore, we conducted a retrospective study of 
the prevalence, clinical features, prognosis, and risk factors 
of prolonged diarrhea in symptomatic patients with fecal 
carriage of C. difficile toxin at a tertiary hospital in Southern 
Taiwan.
Methods
Patients
The National Cheng Kung University Hospital is a medi-
cal center in Southern Taiwan with approximately 1,100 
beds. The Department of Internal Medicine includes eight 
medical wards (369 beds) and four intensive care units 
(ICU, 50 beds). This retrospective study was based on the 
laboratory data from inpatients in the medical department 
in whom C. difficile toxin was detected in fecal samples be-
tween January 1, 2007 and March 31, 2008. Adults, aged ≥ 
18 years, with CDI were included. CDI was defined as the 
presence of fecal C. difficile toxin and concurrent gastroin-
testinal symptoms, such as diarrhea, abdominal discom-
fort or distension, or ileus.8 C. difficile toxin was detected 
by qualitative enzyme immunoassay (PremierTM toxin A&B; 
Meridian Bioscience Inc., Cincinnati, OH, USA).
Data collection
Clinical data, such as demographic information, comor-
bidities, clinical presentations, recent medications within 
30 days of diagnosis of CDI, laboratory parameters ob-
tained 2 days before or 1 day after the diagnosis of CDI, 
radiological findings, and treatment regimens and out-
comes, were obtained from medical records. In addition, 
recurrence rates of CDI, fecal carriage of vancomycin-
resistant Enterococcus (VRE) colonization after antimicro-
bial therapy for CDI, and crude mortality rate at 30 days 
were recorded.
Definitions
Diarrhea was defined as at least three loose or watery stool 
passages within 24 hours for at least 2 consecutive days9, 
and a bowel frequency of less than three loose or watery 
stools per day for at least 48 hours was regarded as recovery 
from diarrhea. Fever was defined as a body temperature ≥ 
38°C. After the prescription of metronidazole treatment, 
diarrhea persisting for more than 7 days was regarded as 
prolonged diarrhea in the study.
CDI was categorized according to the modified classi-
fication proposed by McDonald et al.10 In brief, health-
care facility-onset, healthcare facility-associated CDI is 
defined the onset of CDI more than 48 hours after the ad-
mission of a patient to a healthcare facility. Community-
onset, healthcare facility-associated, CDI is defined as the 
onset of gastrointestinal symptoms of CDI in the com-
munity, or 48 hours or less, after the admission of a pa-
tient to a healthcare facility, provided that symptom onset 
was less than 30 days after the last discharge from a 
healthcare facility.10
CONCLUSION: CDI is increasingly being recognized within the medical departments, and should be 
considered in hospitalized adults with diarrhea, fever, or abdominal distension alone, or in combination.
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Immunosuppression status was regarded as present if 
immunosuppressive agents, or prednisolone ≥ 15 mg/day, 
was given for more than 1 month. CDI was regarded as 
recurring when there was reappearance of fecal C. difficile 
toxin, with relevant symptoms, within 8 weeks of the pre-
vious episode, and at least 10 days after the cessation of 
antibiotic therapy. Chronic kidney disease was defined as 
elevated serum creatinine levels (≥ 1.5 mg/dL) for more 
than 3 months.
A score developed by Charlson et al was used for evaluat-
ing the prognosis based on age and comorbidities.11 The 
weighted index of comorbidity ranged from 0 to 37, and 
with an increasing comorbidity index, the cumulative 
mortality attributable to the comorbidities increased in a 
step-wise fashion.
Statistic analysis
Statistical analysis was performed using SPSS version 13.0 
(SPSS Inc., Chicago, IL, USA). Continuous variables are 
described as mean ± standard deviation. Categorical varia-
bles are described as numbers (percentages). Risk factors 
and mortality rates of CDI with and without prolonged 
diarrhea were compared using the χ2 test. A p value of 
< 0.05 was regarded as statistical significant.
Results
A total of 329 stool samples were tested for C. difficile toxin 
during the study period. Ninety-nine samples from 86 
patients, including 26 patients from the ICU and 60 pa-
tients from the medical wards, had C. difficile toxin, and 
these 86 patients were included for further analysis. Among 
those patients with CDI, six patients received colonoscopy 
examinations, and only one had pseudomembranous col-
itis. The overall incidence of CDI was 42.6 cases per 
100,000 patient-days, or 3.4 cases per 1,000 discharges, 
with an increase in the quarterly incidence during the 
study period (Figure). The incidence was highest in the ICU, 
110.6 cases per 100,000 patient-days. Regarding the inci-
dence in the medical wards; incidence in the infection ward 
(105 per 100,000 patient-days) was higher than in the other 
medical wards.
The clinical characteristics, comorbidities, place of 
acquisition, and risk factors for CDI are shown in 
Table 1. All patients were regarded as having healthcare 
facility-associated infections and most patients (91.9%) 
were hospital-onset. The mean age was 61.1 years (range, 
18–90 years). The mean Charlson comorbidity score was 
6.6 (range, 0–15). Eighty (93.0%) patients had been treated 
with antibiotics in the preceding 30 days before diagnosis, 
and 36 (41.9%) had received more than three antibiotics. 
The most common class of antibiotic administered was 
a third-generation cephalosporin (32 patients, 40.0%). 
Forty-four patients (55.0%) had received proton-pump in-
hibitors (PPIs) or histamine H2-blockers in the preceding 
30 days before diagnosis.
Clinical presentations, laboratory parameters, and clin-
ical outcomes are listed in Table 2. Diarrhea was noted in 
82 (95.3%) patients, and 44 (53.7%) patients had watery 
diarrhea. Abdominal distension was the most frequent 
presentation of abdominal symptoms, noted in 29 (33.7%) 
patients. Fever was detected in 47 (54.7%) patients. The 
mean duration of hospitalization before the diagnosis of 
CDI was 20.6 days (range, 1–259 days). Pus cells were pre-
sent in 15/67 (22.4%) available stool specimens. Eighteen 
patients had been evaluated by abdominal computed 
tomography (CT), and bowel wall thickening (defined as 
a bowel wall thickness of > 3 mm) was detected in eight 
(44.4%) patients.
Metronidazole was the initial therapeutic regimen for 
83 (96.5%) patients, and three patients were not treated due 
to self-limiting courses. Oral vancomycin was substituted 
thereafter in nine (10.8%) patients because of unsatisfactory 
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Figure. Yield rates of Clostridium difficile fecal toxin assay and inci-
dence rates of C. difficile infections among hospitalized patients 
in the Department of Internal Medicine.
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responses to metronidazole therapy. The mean duration 
of treatment was 12.5 days (range, 3–44 days). Prolonged 
diarrhea (≥ 7 days) was found in 31/82 (37.8%) patients. 
Univariate analysis revealed that patients with prolonged di-
arrhea were likely to receive hemodialysis therapy (29.0% vs. 
7.8%, p = 0.026), and had higher Charlson scores (7.9 vs. 6.0, 
Table 2. Clinical presentations, laboratory parameters, 
treatment, and outcome of 86 hospitalized patients with 
Clostridium difficile infections
Clinical featuresa 
Case
(case number with specific data)
Diarrhea 82 (95.3)
 Watery 44 (53.7)
 Loose 34 (41.5)
 Mucus 4 (4.8)
Fever 47 (54.7)
Abdominal distension 29 (33.7)
Abdominal pain 18 (20.9)
Vague discomfort 8 (9.3)
Laboratory data at diagnosis
 Leukocyte count (× 109 cell/mL; n = 84)
  Neutropeniab (n = 13)  362 ± 25 (100–900)
  Non-neutropenia (n = 71) 12,335 ± 102 (800–70,700)
 Creatininec (mg/dL; n = 72) 1.81 ± 2.47 (0.3–12.2)
 CRP (mg/L; n = 73)  106.4 ± 100.3 (7.0–448.4)
 Albumin (g/dL; n = 70) 2.8 ± 0.6 (1.3–4.6)
Antimicrobial therapy
 Metronidazole only 83 (96.5)
 Metronidazole + vancomycin 9 (10.5)
Clinical outcome
 Time to recovery (d; n = 82) 6.0 ± 6.2 (1–29)
 Time to defeverence (d; n = 47) 6.5 ± 4.8 (1–20)
 Prolonged diarrhea after 31 (36.4)
  metronidazole therapy
 Recurrence 7 (8.1)
 Vancomycin-resistant 3 (3.5)
  Enterococcus colonization
In-hospital mortality rate  32 (37.2)
aData presented as n (%) or mean ± standard deviation (range); bneu-
tropenia related to chemotherapy is defined as less than 0.5 × 109/L 
of neutrophil count; cexcluding those with end-stage renal stage 
requiring hemodialysis or peritoneal dialysis. CRP = C-reactive 
protein.
Table 1. Clinical characteristics and risk factors of 86 hospi-
talized patients with Clostridium difficile infections
Clinical characteristics Casea
Age, ≥ 65 yr 47 (54.7)
Sex, male 44 (51.2)
Hospitalization in prior 30 days 38 (44.2)
 before diagnosis
Nursing home residency 5 (5.8)
Locationb
 Medical ICU 23/110.6 (26.7)
 Oncology ward 29/66.7 (33.7)
 Infection ward 10/105.0 (11.6)
 Nephrology ward 8/59.4 (9.3)
 Gastrointestinal ward 6/25.1 (7.0)
 Other medical wards 10/12.0 (11.6)
Comorbidity 
 Malignancy 37 (43.0)
 Diabetes mellitus 28 (32.6)
 Chronic kidney disease 24 (27.9)
 Hemodialysis 13 (15.1)
 Liver cirrhosis 13 (15.1)
 HIV infection 2 (2.3)
Recent therapeutic interventionc 
 Tube feeding 42 (48.8)
 Chemotherapy 23 (26.7)
 Endotracheal tube or tracheostomy 20 (23.3)
 Mechanical ventilation 17 (19.7)
 Immunosuppression 9 (10.5)
Recent medicationsc,d 
 Antimicrobial therapy
  1st generation cephalosporin 4 (5.0)
  2nd generation cephalosporin 5 (6.3)
  3rd generation cephalosporin 32 (40.0)
  4th generation cephalosporin 27 (33.8)
  Penicillin/β-lactamase inhibitor 26 (32.5)
  Fluoroquinolones 26 (32.5)
  Glycopeptides  23 (28.8)
  Carbapenem 21 (26.3)
  Penicillins 13 (16.3)
  Macrolides 8 (10.0)
  Aminoglycosides  4 (5.0)
  Clindamycin 3 (3.8)
Proton-pump inhibitors 41 (51.3)
Antifungal agents 14 (17.5)
Histamine H2-blockers 3 (3.8)
aData presented as n (%) or case/100,000 patient-days (%); bnumber/
incidence (case/100,000 patient-days); crecent medications and 
interventions were given within 30 days prior to the diagnosis of 
Clostridium difficile infections; donly 80 patients received recent medi-
cation. ICU = Intensive care unit.
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p = 0.024) than those without prolonged diarrhea (Table 3). 
Recurrence of CDI occurred in seven (8.1%) patients.
VRE colonization was found in five (5.8%) patients, and 
three VRE isolates were discovered after the initialization 
of antimicrobial therapy for CDI. The mean hospital stay 
after diagnosis of CDI was 25.7 days (range, 2–176 days). 
The crude 30-day mortality was 23.3%, and all-cause in-hos-
pital mortality was 37.2%. There was no difference in crude 
30-day mortality between patients with and without pro-
longed diarrhea (23.5% vs. 25.8%, p = 1.000). However, in-
hospital mortality rates were higher in those patients with 
prolonged diarrhea (29% vs. 54.8%, p = 0.035; Table 3).
Discussion
In this study, the incidence of CDI was 42.6 cases per 
100,000 patient-days, or 3.4 cases per 1,000 discharges, 
which is compatible with the data from the Canadian 
nosocomial surveillance between November 2004 and 
April 2005 (i.e. 65 cases per 100,000 patient-days, or 4.6 
cases per 1,000 admissions),12 and the recorded 3.3 pa-
tients per 1,000 hospital discharges in Oregon, USA from 
1995 to 2002.5 With regard to Southeast Asia, the inci-
dence in Singapore was 3.2 cases per 1,000 admissions, or 
53.8 cases per 100,000 patient-days, between October 
2002 and February 2003.13 A recent study of patients in 
two infection wards and six medical ICUs in a tertiary 
hospital in Northern Taiwan revealed an incidence of 120 
cases per 100,000 patient-days.14 However, increasing inci-
dence rates were noted during the surveillance, and variable 
incidences among medical wards were noted, which may be 
partly related to the different clinical characteristics of the 
hospitalized patients in the different units, such as underly-
ing illnesses, and antibiotics or PPIs exposure. The familiar-
ity with CDI among the attending physicians in these units 
might also influence the attempts to diagnose CDI, and 
thereafter its incidence. Also, it was a retrospective study in 
which clinical data were retrieved from symp tomatic patients 
with C. difficile toxin in feces, and the C. difficile toxin test was 
not covered by health insurance. The incidence of patients 
with CDI was, therefore, likely to be underestimated.
Not surprisingly, diarrhea was common in patients 
with CDI. Previous guidelines for C. difficile-associated di-
arrhea recommended that tests for C. difficile should be 
Table 3. Univariate analysis of factors associated with prolonged diarrhea with Clostridium difficile infections
Variablea Mild diarrhea (n = 51) Prolonged diarrhea (n = 31) p
Sex, male 25 (49.0) 15 (48.4) 0.654
Age 59.9 ± 19.7 62.7 ± 18.0 0.513
Recent hospitalization 24 (47.1) 14 (45.2) 1.000
ICU admission 13 (25.5) 13 (41.9) 0.146
Comorbidity
 Diabetes mellitus 14 (27.5) 12 (38.7) 0.333
 Chronic kidney disease 11 (21.6) 13 (41.9) 0.079
 Hemodialysis 4 (7.8) 9 (29.0) 0.026
 Malignancy 21 (41.2) 12 (38.7) 0.589
 Neutropeniab 9 (17.6) 4 (12.9) 0.757
 Charlson score 6.0 ± 3.6 7.9 ± 3.6 0.024
Clinical Outcomes
 Recurrence 3 (5.9) 4 (12.9) 0.417
 30-day mortality 12 (23.5) 8 (25.8) 1.000
 In-hospital mortality 15 (29.4) 17 (54.8) 0.035
aData presented as n (%) or mean ± standard deviation; bneutropenia is defined as less than 0.5 × 109/L of neutrophil count. ICU = Intensive 
care unit.
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done in patients with diarrhea.8 However, some patients 
may present with abdominal distension and pain without 
diarrhea, which can be the case in 8–50% of CDI compli-
cated with fulminant colitis, or in postoperative cases 
with ileus.15 In the present series, four (4.7%) patients did 
not have diarrhea, but presented with fever (4 patients), 
abdominal pain (2 patients) or distention (2 patients). 
Three of the four patients had concurrent leukocytosis. 
Wanahita et al analyzed 60 patients with unexplained leu-
kocytosis, and 35 (58.3%) patients were diagnosed with 
CDI; 7/35 (20.0%) of these patients did not report di-
arrhea.16 There fore, in hospitalized patients with unex-
plained abdominal discomfort and leukocytosis, CDI 
should be considered as a differential diagnosis. However, 
another common test given to hospitalized patients with 
diarrhea, the fecal leukocyte test, was performed in 66/86 
patients with CDI, and positive results were noted in 15 
(22.7%) patients. Due to the low sensitivity rate of 30%,17 
the routine use of the fecal leukocyte test is not necessary 
for CDI patients.
CT scans are not routinely performed for CDI. In our 
patients, only 8/18 (44.4%) who underwent abdominal CT 
examination were found to have bowel wall thickening. 
None had the uncommon, but specific, CT finding for 
C. difficile colitis, nodular fold thickening, or so called “ac-
cordion sign”.18 A previous study reported abnormal wall 
thickening in 50–76% of patients with CDI by abdominal 
CT scanning.19 Despite CT scanning not being a diagnostic 
tool for CDI, it can be useful in distinguishing severe dis-
eases from mild-to-moderate infections, and to evaluate 
the need for surgical intervention.
PPIs have been proposed as risk factors for CDI.3 In 
this study, PPIs were given to 41/86 (47.7%) patients within 
the 30 days before diagnosis of CDI. However, this was 
not a case-control study, so we cannot plot the association 
between CDI and PPI use. Further case-control studies 
will be performed.
Oral metronidazole has been recommended as the first 
line treatment for mild and moderate CDI, in part due to 
cost effectiveness and, in part due to the concern that oral 
vancomycin may be more likely to promote colonization 
by VRE.20 In this study, VRE colonization was detected 
in 5/86 (5.8%) patients. Previous studies suggest that 
metronidazole and extended-spectrum cephalosporins 
will increase the risk of VRE acquisition.21 Moreover, in a 
prospective observational study, Al-Nassir et al found that 
oral metronidazole and vancomycin therapy specific 
for CDI could promote VRE overgrowth, and both were 
recognized as risk factors for fecal VRE colonization.22 
With the increasing threat of VRE in modern medicine, 
new agents with less effect on intestinal microflora are 
desperately needed for the treatment of CDI.
The clinical resolution of diarrhea associated with CDI 
was always noted within 2–3 days after antimicrobial ther-
apy, and complete resolution ensued within 7–10 days.23 
The mean duration of diarrhea after the start of treatment 
was 6 days in the present study, which was comparable to 
that of an Israeli study of nosocomial diarrhea (mean, 
6 days; range, 1–40 days).24 However, after appropriate 
metronidazole treatment for 1 week, more than one-third 
(36.4%) of patients still had diarrhea, similar to the results 
of Hardt et al (37%).25 The crude mortality rate at 30 days 
in this series was 23.3%. The in-hospital mortality rate in 
our study was significantly higher in those patients with 
prolonged diarrhea, up to 54.8%. It is speculated that the 
death of patients with prolonged diarrhea could be attrib-
uted to underlying morbidity rather than to the compli-
cations associated with CDI.
In conclusion, CDI was increasingly recognized during 
this study, especially in ICU patients. Although diarrhea 
was the most common symptom, CDI should be consid-
ered in hospitalized adults with diarrhea, fever, or abdom-
inal distension alone, or in combination.
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